多发性骨髓瘤患者BCMA CAR-T治疗后长期血细胞减少的分子机制
本研究纳入48例接受BCMA CAR-T治疗的多发性骨髓瘤患者,血细胞减少总发生率为95.7%,输注后1个月3级以上血小板减少和中性粒细胞减少分别占57%和53%,1年后仍分别有4例和3例存在。体外实验表明活化的CAR-T细胞上清液通过旁分泌作用阻滞造血干祖细胞分化,联合干扰素γ、肿瘤坏死因子α/β、转化生长因子β、白介素-6和白介素-17抑制剂可预防此效应。
要点
- BCMA CAR-T治疗后血细胞减少总发生率为95.7%,1个月时3级以上血小板减少和中性粒细胞减少分别占57%和53%。
- 基线血细胞减少和高峰值炎症标志物与持续至3个月的血细胞减少高度相关。
- 活化的CAR-T细胞上清液通过旁分泌作用阻滞造血干祖细胞分化,联合细胞因子抑制剂可预防。
核心结论
- CAR-T活化通过旁分泌效应诱导造血干祖细胞成熟阻滞,为减轻该毒性提供了潜在治疗方法。
研究设计与样本
- 本研究对48例接受BCMA CAR-T细胞治疗的多发性骨髓瘤患者进行了特征分析,以了解血细胞减少的动力学、识别预测因素并确定潜在机制。
- 采用体外髓系分化模型评估BCMA CAR-T细胞对造血干祖细胞分化的旁分泌效应。
- 进行单细胞RNA测序分析转录因子和调节子活性变化。
主要发现
- 血细胞减少总体发生率为95.7%,输注后1个月3级以上血小板减少和中性粒细胞减少分别见于57%和53%的患者,1年后仍分别有4例和3例患者存在。
- 基线血细胞减少和高峰值炎症标志物与持续至3个月的血细胞减少高度相关。
- 活化的CAR-T细胞上清液(spCAR)表型分析显示其阻止造血干祖细胞分化,促进更未成熟表型,联合干扰素γ、肿瘤坏死因子α/β、转化生长因子β、白介素-6和白介素-17抑制剂可预防此效应。
- 单细胞RNA测序显示spCAR存在时早期造血分化相关转录因子GATA2、RUNX1、CEBPA上调,而参与中性粒细胞和单核细胞成熟的关键调节子ID2和MAFB活性下降。
临床怎么用
- 作者认为CAR-T活化通过旁分泌效应诱导造血干祖细胞成熟阻滞,并提供潜在治疗方法以减轻该毒性的严重程度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CAR-T) therapies, being particularly severe among patients with relapsed or refractory multiple myeloma (MM). In this study, we characterized 48 patients treated with B-cell maturation antigen (BCMA) CAR-T cells to understand kinetics of cytopenia, identify predictive factors, and determine potential mechanisms underlying these toxicities. We observed that overall incidence of cytopenia was 95.7%, and grade >3 thrombocytopenia and neutropenia, 1 month after infusion, was observed in 57% and 53% of the patients, respectively, being still present after 1 year in 4 and 3 patients, respectively. Baseline cytopenia and high peak inflammatory markers were highly correlated with cytopenia that persisted up to 3 months. To determine potential mechanisms underlying cytopenias, we evaluated the paracrine effect of BCMA CAR-T cells on hematopoietic stem and progenitor cell (HSPC) differentiation using an ex vivo myeloid differentiation model. Phenotypic analysis showed that supernatants from activated CAR-T cells (spCAR) halted HSPC differentiation, promoting more immature phenotypes, which could be prevented with a combination of interferon γ, tumor necrosis factor α/β, transforming growth factor β, interleukin-6 (IL-6) and IL-17 inhibitors. Single-cell RNA sequencing demonstrated upregulation of transcription factors associated with early stages of hematopoietic differentiation in the presence of spCAR (GATA2, RUNX1, CEBPA) and a decrease in the activity of key regulons involved in neutrophil and monocytic maturation (ID2 and MAFB). These results suggest that CAR-T activation induces HSPC maturation arrest through paracrine effects and provides potential treatments to mitigate the severity of this toxicity.
引用
- Palacios-Berraquero ML, Rodriguez-Marquez P, Calleja-Cervantes ME, et al. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma. Blood Adv. 2024. PMID: 39058976. doi:10.1182/bloodadvances.2023012522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。